-
Mashup Score: 4Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) - 3 year(s) ago
AbstractAims. In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial (COLCOT) of 4745 patients enrolled within 30 days after myocardial
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7
AbstractAims. The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aim
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Time-to-treatment initiation of #colchicine and #CVE after #MI in the #COLCOT. #cardiotwitter https://t.co/4E5MkPMc21
-
-
Mashup Score: 3
FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.https://www.ahajournals.org/journal/circFrançois Roubille, MD, PhD, Cardiology Department, Montpellier University Hospital, Montpellier University, 371, Avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex 05, France. Email f-roubille@chu-montpellier.frReferences1….
Source: CirculationCategories: Cardiac Surgery, Latest HeadlinesTweet-
#Editorial: Colchicine for secondary CV prevention: Comparison of #COLCOT, #COPS and #LoDoCo2 https://t.co/Boet0C1F5h #AHAjournals https://t.co/LtWad8RyJy
-
-
Mashup Score: 2Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - 5 year(s) ago
The present meta-analysis consolidated evidence from recent trials to evaluate the efficacy and safety of low-dose colchicine for secondary cardiovascular prevention among CAD patients on standard medical therapy. Compared to placebo or no colchicine, colchicine was associated with a significant reduction in the incidence of the primary composite endpoint [pooled HR 0.68 (95% CI 0.54-0.81)]. In…
Source: Canadian Journal of CardiologyCategories: Cardiologists, Latest HeadlinesTweet-
RT @MoAlkhalafPhD: ⬇️Indeed a great recap of #COLCOT & new meta analysis publication @CJC_JCC 🔗 https://t.co/YyPHEriIT3 💫Important point…
-
-
Mashup Score: 6
AbstractAims. The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We ai
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
RT @Open_HeartBMJ: #COLCOT Trial Time-to-treatment initiation of #colchicine & CV outcomes after MI https://t.co/XhAKzJ2QWu #ESCCongress h…
-
-
Mashup Score: 1
AbstractAims. The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We ai
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#COLCOT Trial Time-to-treatment initiation of #colchicine & CV outcomes after MI https://t.co/XhAKzJ2QWu #ESCCongress https://t.co/B4RICVXpYl
-
-
Mashup Score: 3Safety and efficacy of colchicine in patients with coronary artery disease: A systematic review and meta-analysis - 5 year(s) ago
Given current evidence, the use of colchicine for the prevention of adverse cardiovascular events in patients with coronary artery disease (CAD) remai…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
What started with an @TJUHospital Cardiology Journal Club conversation on #COLCOT led to publication of our meta-analysis by @vakasullah @AbingtonJeff https://t.co/7XYXyEz5oF @mmamas1973 @DocSavageTJU @ron_waksman @SABOURETCardio #cardiotwitter #ACCFIT
-
-
Mashup Score: 3Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication? - 5 year(s) ago
Inflammation as a cardiovascular risk factor has attracted increasing attention . The current standard of care for decreasing the occurrence of cardiovascular events includes controlling risk factors such as hypertension and maximizing the lowering of low-density lipoprotein cholesterol (LDL-C). However, a recent study demonstrated decreased cardiovascular risk with the anti-inflammatory agent…
Categories: Cardiologists, Latest HeadlinesTweet-
Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication? | SpringerLink #cardiotwitter #COLCOT https://t.co/E5fAqOgIaQ
-
-
Mashup Score: 11
A cost analysis of findings from the COLCOT trial showed that the addition of low-dose colchicine therapy to standard care after MI resulted in a 69% lifetime cost reduction compared with standard care alone. Further, the addition of low-dose (0.5 mg once daily) colchicine to standard care resulted in a 47% average cost decrease, in the COLCOT trial ($265 vs. $502 Canadian dollars at 2 years)
Source: www.healio.comCategories: Cardiology News and JournalsTweet-
#COLCOT: Cost analysis showed the addition of low-dose colchicine therapy to standard care after MI resulted in a 69% lifetime cost reduction compared with standard care alone. @ICMtl @ACCinTouch #ACC20 https://t.co/G9Vku6ij45
-
#COLCOT and cost-effectiveness: adding colchicine after #myocardial #infarction as an effective and even cost-saving strategy: https://t.co/PXHrY03cgf @cpgale3 @diogoasantosfer #EHJQCCO #cardiotwitter https://t.co/Veo4AiEIhi